US3039933A - Ethyl cellulose-polyethylene glycol tablet matrix - Google Patents
Ethyl cellulose-polyethylene glycol tablet matrix Download PDFInfo
- Publication number
- US3039933A US3039933A US688403A US68840357A US3039933A US 3039933 A US3039933 A US 3039933A US 688403 A US688403 A US 688403A US 68840357 A US68840357 A US 68840357A US 3039933 A US3039933 A US 3039933A
- Authority
- US
- United States
- Prior art keywords
- tablet
- active ingredient
- solid
- release
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011159 matrix material Substances 0.000 title claims description 36
- 229920001223 polyethylene glycol Polymers 0.000 title claims description 25
- 239000002202 Polyethylene glycol Substances 0.000 title claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title description 2
- 239000003826 tablet Substances 0.000 claims description 74
- 239000004480 active ingredient Substances 0.000 claims description 48
- 239000007787 solid Substances 0.000 claims description 30
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 19
- 229920001249 ethyl cellulose Polymers 0.000 claims description 19
- 239000001856 Ethyl cellulose Substances 0.000 claims description 18
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 12
- -1 FATTY ACID ESTERS Chemical class 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 8
- 239000011343 solid material Substances 0.000 claims description 6
- 230000007721 medicinal effect Effects 0.000 claims description 5
- 239000007891 compressed tablet Substances 0.000 claims description 4
- 239000006104 solid solution Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000007423 decrease Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 230000006835 compression Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002195 soluble material Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 2
- 241001508687 Mustela erminea Species 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 2
- 229960003839 dienestrol Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229960004482 quinidine sulfate Drugs 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- BCXHDORHMMZBBZ-DORFAMGDSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC BCXHDORHMMZBBZ-DORFAMGDSA-N 0.000 description 1
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- PGNKBEARDDELNB-UHFFFAOYSA-N Diethylcarbamazine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)C(=O)N1CCN(C)CC1 PGNKBEARDDELNB-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RHTNTTODYGNRSP-UHFFFAOYSA-N Tolazoline hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC1=NCCN1 RHTNTTODYGNRSP-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 229940008238 amphetamine sulfate Drugs 0.000 description 1
- 229960003482 antazoline hydrochloride Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 1
- 229960002123 bethanechol chloride Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960003871 codeine sulfate Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940119751 dextroamphetamine sulfate Drugs 0.000 description 1
- 229960004837 diethylcarbamazine citrate Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004842 ephedrine sulfate Drugs 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 229950008987 mercurophylline Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- SWKDMSRRIBZZAY-UHFFFAOYSA-N n-benzyl-n-(4,5-dihydro-1h-imidazol-2-ylmethyl)aniline;hydrochloride Chemical compound Cl.N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 SWKDMSRRIBZZAY-UHFFFAOYSA-N 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 229960001499 neostigmine bromide Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229960002139 pilocarpine hydrochloride Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 229940018203 pyrilamine maleate Drugs 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- JTDRBSMSKQRBGT-UHFFFAOYSA-L sodium;1,3-dimethyl-7h-purine-2,6-dione;mercury(2+);3-(2-methoxypropylcarbamoyl)-1,2,2-trimethylcyclopentane-1-carboxylate;hydroxide Chemical compound [OH-].[Na+].[Hg+2].O=C1N(C)C(=O)N(C)C2=C1NC=N2.COC([CH2-])CNC(=O)C1CCC(C)(C([O-])=O)C1(C)C JTDRBSMSKQRBGT-UHFFFAOYSA-L 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229960002649 tolazoline hydrochloride Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Definitions
- medication is taken at widely spaced times and this results in an intermittent response characterized by an increase in intensity of action each time the medication is taken followed by a falling off of action after each dose. In accordance with the present invention, however, this is avoided, and the action of the tablet is more uniform.
- My invention accordingly consists in the combinations of compositions and series of steps which will be exemplified in the tablets and methods hereinafter described and of which the scope of application will be indicated in the appended claims.
- a medicated tablet conventionally constitutes a solid carrier and a medically active ingredient hereinafter sim ply referred to as an active ingredient.
- the solid carrier ordinarily is inert, that is to say, it usually has no medical function, simply serving as a diluent. It is nontoxic, tasteless and bland, and lends itself to tableting, this being a standard operation in which a mass of particles of a solid carrier and active ingredient are compacted in a die under pressure.
- the present invention distinguishes from conventional tableting only in that a different and special solid carrier is used. In all other respects, that is to say, in the mixing together of the solid carrier and active ingredient or ingredients, and in the tableting operation itself, standard practice is followed.
- my invention consists in the provision of a solid carrier which constitutes a homogeneous matrix consisting of a water-soluble material intimately, extensively, finely and thoroughly dispersed in a water-insoluble material, the active ingredient being finely, intimately, extensively and thoroughly dispersed in the matrix itself.
- the two constituents of the matrix are in solid solution with one another.
- the matrix it is highly preferred, moreover, for the matrix to have waxy physical characteristics, so that the particles thereof have excellent coherency, thus enabling the tablet to maintain its shape, and, furthermore, permitting the tablet to slip off, i.e., readily release, from the tableting dies.
- the water-soluble ingredient of the matrix constitutes polyethylene glycol or a water-soluble fatty acid ester thereof both of these being waxy, and the water-insoluble ingredient is ethyl cellulose.
- any of the commercially available polyethylene glycols are suitable for the purposes of my invention and prefer particularly to use polyethylene glycols or the specified derivatives thereof) having an average molecular weight of between 1,000 and 20,000.
- a suitable water-soluble fatty acid ester of polyethylene glycol is a mono or di stearate of polyethylene glycol wherein the molecular weight of the polyethylene glycol is about 6,000.
- ethyl celluloses which have an ethyoxyl content of from 2.2 to 2.6 ethyoxyl groups per anhydroglucose unit.
- the number of such anhydroglucose units in a chain that is to say, the molecular Weight, has no noticeable effect on the operation of my invention, and I have found that both high and low viscosity types of ethyl cellulose work equally well.
- the first step in the operation of my invention is to prepare a base matrix mixture for the tablet.
- One satisfactory method of making the same is to dissolve the water-soluble and water-insoluble ingredients in a mutual volatile organic solvent, and then to evaporate the solvent so as to obtain a single homogeneous solid.
- this solid the two materials, i.e., the water-soluble and the water-insoluble constituents, will be intimately, finely, extensively and thoroughly dispersed in one another. Thereafter, this homogeneous solid is milled, that is to say, reduced to fine particles, e.g., 20 mesh.
- the matrix material is ready for mixing with the active ingredients and tableting. It can be stored for as long as desired and is at all times immediately available for incorporation in a tablet.
- the same is mixed with an active ingredient in any desired proportions, depending upon the desired rate of release and the desired amount of medication.
- the amount of active ingredient does not exceed 40% by weight of the tablet and in no case should it exceed by weight.
- the mixing can be accomplished in conventional blenders and mixers, such as are presently employed in phar- 3 mac eutical houses. Thereafter, the mixture of the matrix material and the active ingredient are tableted in a known manner, i.e., between dies and under pressure. In the finished tablet, the active ingredient will be found to be finely, intimately, extensively and thoroughly dispersed through the matrix.
- An example of the foregoing method consists in dissolving two pounds of polyethylene glycol (molecular weight of 6,000) with one pound of ethyl cellulose (2.42 to 2.53 ethyoxyl groups per anhydroglucose unit, the viscosity being 4 centipoises when determined in 5% concentration, using 80% toluene and 20% methanol as a solvent) in three gallons of methanol at room temperature.
- the solution then is evaporated in a vacuum drier at any suitable temperature in order to recover the methanol for reuse. If recovery is not desired, the solvent can be evaporated into the atmosphere at room temperature.
- the resulting homogeneous solid then is milled to a fineness of about 20 mesh.
- An alternate method of making the matrix material is to heat the polyethylene glycol or the water-soluble fatty acid ester thereof so as to melt the same, and then to dissolve the ethyl cellulose in the now liquid material.
- the temperature employed for melting is a few degrees, a minimum of 5 C., above the melting temperature for the polyethylene glycol or its derivative, e.g., about 60 C.
- the ethyl cellulose is completely dissolved and, preferably, after the mix is stirred, it is permitted to solidify by cooling, and it will be found that at such time the two materials are as finely, thoroughly, intimately and uniformly dispersed in one another as in the first method above described. Thereafter, the solid is milled and used in the manner already set forth.
- -A tablet prepared in accordance with the foregoing invention Will, when ingested, be exposed to the fluids present in the alimentary canal. These are water based and, therefore, at the solid-liquid interface of the tablet and alimentary fluid a disintegrative process will be started by solution or dispersion of the water-soluble material, and also a release, therefore, of the water-insoluble material in the matrix. This will set free as much active ingredient as previously had been bound into the tablet by that amount of the water-soluble and waterinsoluble materials that have left the surface of the tablet. In other words, as the surface of the tablet gradually is disintegrated by the water present in the alimentary systern, the active ingredient content will be released into the system for assimilation thereby.
- the rate of disintegration of the tablet and, therefore, the rate of release of the active ingredient can be varied by varying the composition of the matrix and, in general, the greater the percentage of water-soluble material present, the more rapid will be the rate of release and vice versa.
- matrices of different compositions which will give times of disintegration ranging from one hour to twenty-four hours for a single conventionally-sized tablet.
- a diameter tablet with oval sides containing five grains of matrix consisting of 55% ethyl cellulose and 45% polyethylene glycol, with a molecular weight of 6,000, prepared at a typical tableting compression force of 35 tons per square inch, will slowly disintegrate over a period of about four hours, it being then fully disintegrated.
- the time required for complete slow disintegration is about 2 hours.
- the time for complete slow disintegration is about 6 hours. If the amount of ethyl cellulose is 65% and that of polyethylene glycol is 35%, the time for complete slow disintegration is about 9 hours.
- the time span of dis integration may be extended or shortened bymaking the 4 weight of the tablet larger or smaller as the case may be, or by changing the shape of the tablet, the disintegration time being a function of the ratio of surface area to volume.
- any known type of active ingredient can be utilized, examples thereof being: racemic amphetamine sulfate, dextroarn-phetamine sulfate, erythrityltetranitrate, digitoxin, acetyl salicylic acid, sodium penicillin, dihydrostreptomycin, pentobarbital, tolbutamide, aminophylline, antazoline hydrochloride, pyrilamine 'maleate, alkaloids of belladonna, bethanecholchloride, caffeine, codeine sulfate, morphine sulfate, colchicine, cortisone, meprobamate, tolazoline hydrochloride, reserpine, quinidine sulfate, quinine sulfate, pilocarpine hydrochloride progestrone, dienestrol, diethyl carbamazine citrate, ephedrine sulfate, ergonovine meleate
- the active ingredient may itself be carried in an inert base, particularly when very tiny amounts thereof are to be utilized, or when the active ingredient normally is supplied in such manner by chemical and pharmaceutical manufacturing concerns.
- a typical example of a tablet embodying my invention is 5 mgs. of dextroamphetamine sulfate together sufficient of the matrix to make up 5 grains (325 mgs.), the matrix consisting of 65 by weight of ethyl cellulose and 35% by weight of polyethylene glycol.
- the tablet is compressed at 35 tons per square inch and has a diameter of A; of an inch.
- Another example is a tablet of the same weight, 5 grains, the same size, and similar compression, containiug mgs. of pyrilamine maleate together with a suflicient quantity of the same matrix as used in example 1 to make up the 5 grain-s.
- Still another example is a tablet of the same size, weight and compression, containing 2 mgs. of dienestrol together with enough of the same matrix to make up 5 grains.
- a further example is a tablet of the same weight, size and compression, containing 0.5 mg. of reserpine together with enough of the matrix to make up to 5 grains.
- Still another example is a tablet containing 200 mgs. of quinidine sulfate together with enough of the same matrix to make up an 8 grain tablet. Due to the size of the tablet, the same is /2 inch in diameter and is compressed to the same extent as aforesaid.
- the matrix materials of my invention not only are non-toxic, bland, inert, palatable, and ingestible in the human system without any ill effects, but they can be stored for protracted periods of time without experiencing any chemical or physical deterioration.
- the release of the active ingredient takes place by solution or dispersion at the surface of the tablet, and because the surface initially is largest directly following ingestion, the initial release of active ingredient is the fastest, and thereafter the rate of release gradually decreases. This is particularly desirable because it enables a rapid achievement of a therapeutic level of medication to be obtained, followed by a slowly decreasing rate of release which approximates the rate at which the body eliminates the medication.
- the tablet differs from some conventional tablet-s which are specially coated to provide release only in regions of certain pHs and which, after they travel past such regions, will have no beneficial effect.
- a tablet embodying my invention can be coated to prevent release of medicament initially and to permit start of release only at some certain part of the alimentary canal.
- a solid compressed tablet having a slow protracted medicinal effect said tablet consisting of a matrix and an active ingredient, said matrix essentially constituting a solid solution of solid ethyl cellulose in a solid material selected from the class consisting of polyethylene glycol and water-soluble mono and di fatty acid esters thereof, said active ingredient being intimately, finely, extensively and thoroughly dispersed throughout said matrix, whereby when the tablet is ingested, the water based liquids in the alimentary canal will form a liquid-solid interface, with the surface of the tablet, whereupon the surface of the tablet will gradually be disintegrated by solution of the solid material selected from the class consisting of polyethylene glycol and water-soluble mono and di fatty acid esters thereof in the alimentary water-based liquids with the consequent release of the solid ethyl cellulose and of the active ingredient so that the tablet will slowly disintegrate at its surface to slowly and continually release the active ingredient at the said surface into the alimentary canal over a period of several hours and so that because the rate of release of the active ingredient is
- a solid compressed tablet having a slow protracted medicinal effect said tablet consisting of a matrix and an active ingredient, said matrix essentially constituting a solid mutual solution of solid polyethylene glycol having a molecular Weight of between 1,000 and 20,000 and solid ethyl cellulose having an ethyoxyl content of from 2.2 to 2.6 ethyoxyl groups per anhydroglucose unit, said active ingredient being intimately, finely, extensively and thoroughly dispersed throughout said matrix, whereby when the tablet is ingested, the water-based liquids in the alimentary canal will form a liquid-solid interface, with the surface of the tablet, whereupon the surface of the tablet will gradually be disintegrated by solution of the solid material selected from the class consisting of polyethylene glycol and water-soluble mono and di fatty acid esters thereof in the alimentary water-based liquids with the consequent release of the solid ethyl cellulose and of the active ingredient so that the tablet will' slowly disintegrate at its surface to slowly and continually release the active ingredient at the said surface into
- a solid compressed tablet having a slow protracted medicinal effect said tablet consisting of a matrix and an active ingredient, said matrix essentially constituting a solid solution of a solid fatty acid ester of a polyethylene glycol having a molecular weight of between 1,000 and 20,000 and solid ethyl cellulose having an ethyoxyl content of from 2.2 to 2.6 ethyoxyl groups per anhydroglucose unit, said active ingredient being intimately, finely, extensively and thoroughly dispersed throughout said matrix, whereby when the tablet is ingested, the water-based liquids in the alimentary canal will form a liquid-solid interface, with the surface of the tablet, whereupon the surface of the tablet will gradually be disintegrated by solution of the solid material selected from the class consisting of polyethylene glycol and Water-soluble mono and di fatty acid esters thereof in the alimentary waterbased liquids with the consequent release of the solid ethyl cellulose and of the active ingredient so that the tablet will slowly disintegrate at its surface to slowly and continually release the
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent Ofitice 3,939,933 Patented June 19, 1962 3,039,933 ETHYL CELLULOSE-POLYETHYLENE GLYCOL TABLET MATRIX Robert Goldman, Cresskill, N.J., assignor to Premo Pharmaceutical Laboratories, Inc., South Hackensack, NJ., a corporation of New Jersey No Drawing. Filed Oct. 7, 1957, Ser. No. 688,403 3 Claims. (Cl. 167-82) This invention relates to a tablet having a slow protracted medicinal effect and to a method of making the same.
More particularly, it is an object of my invention to provide a tablet and method of the character described which are such that the tablet after ingestion, i.e., after being swallowed, experiences a time-controlled slow disintegration, so that an active medicinal ingredient or ingredients uniformly and finely dispersed throughout the tablet is continually discharged for assimilation by the patient.
It is another object of my invention to provide a tablet and method of the character described which make the taking of medication more convenient.
It is another object of my invention to provide a tablet and method of the character described which are such that a single tablet taken in the morning, for example, will relieve the patient entirely of the necessity of carrying a supply of medication with him during the day and also of the necessity of remembering to take the medication at prescribed intervals.
It is another object of my invention to provide a tablet and method of the character described which will provide a more uniform therapeutic response than can be achieved with doses taken at intervals. Customarily, medication is taken at widely spaced times and this results in an intermittent response characterized by an increase in intensity of action each time the medication is taken followed by a falling off of action after each dose. In accordance with the present invention, however, this is avoided, and the action of the tablet is more uniform.
It is another object of my invention to provide a tablet and method of the character described which will reduce the manufacturers costs and will enable any kind of active ingredient to be used therewith.
It is another object of my invention to provide a tablet and method of the character described which lend themselves to manufacture by comparatively unskilled labor and which do not require the use of special equipment.
It has been proposed heretofore to provide medication having an extended effective period although taken at a single dose. Such medication constituted many individual small particles of an active ingredient which were covered with coatings requiring different times for dissolution, so that after ingestion of a large number of mixed particles of such character, the release of medication was extended over a period of time determined by the varying times necessary for the different coatings to dissolve. However, such medication customarily had different rates of release time depending on the pH of the site in which it would dissolve.
It is another object of my invention to provide a tablet and method of the character described which avoid the drawback that just has been mentioned.
Other objects of my invention in part will be obvious and in part will be pointed out hereinafter.
My invention accordingly consists in the combinations of compositions and series of steps which will be exemplified in the tablets and methods hereinafter described and of which the scope of application will be indicated in the appended claims.
A medicated tablet conventionally constitutes a solid carrier and a medically active ingredient hereinafter sim ply referred to as an active ingredient. The solid carrier ordinarily is inert, that is to say, it usually has no medical function, simply serving as a diluent. It is nontoxic, tasteless and bland, and lends itself to tableting, this being a standard operation in which a mass of particles of a solid carrier and active ingredient are compacted in a die under pressure.
The present invention distinguishes from conventional tableting only in that a different and special solid carrier is used. In all other respects, that is to say, in the mixing together of the solid carrier and active ingredient or ingredients, and in the tableting operation itself, standard practice is followed.
Essentially, my invention consists in the provision of a solid carrier which constitutes a homogeneous matrix consisting of a water-soluble material intimately, extensively, finely and thoroughly dispersed in a water-insoluble material, the active ingredient being finely, intimately, extensively and thoroughly dispersed in the matrix itself. Desirably, the two constituents of the matrix are in solid solution with one another. It is highly preferred, moreover, for the matrix to have waxy physical characteristics, so that the particles thereof have excellent coherency, thus enabling the tablet to maintain its shape, and, furthermore, permitting the tablet to slip off, i.e., readily release, from the tableting dies.
In the preferred form of my invention the water-soluble ingredient of the matrix constitutes polyethylene glycol or a water-soluble fatty acid ester thereof both of these being waxy, and the water-insoluble ingredient is ethyl cellulose.
I have found that any of the commercially available polyethylene glycols are suitable for the purposes of my invention and prefer particularly to use polyethylene glycols or the specified derivatives thereof) having an average molecular weight of between 1,000 and 20,000. A suitable water-soluble fatty acid ester of polyethylene glycol is a mono or di stearate of polyethylene glycol wherein the molecular weight of the polyethylene glycol is about 6,000.
Any of the commercially available ethyl celluloses can be used which have an ethyoxyl content of from 2.2 to 2.6 ethyoxyl groups per anhydroglucose unit. The number of such anhydroglucose units in a chain, that is to say, the molecular Weight, has no noticeable effect on the operation of my invention, and I have found that both high and low viscosity types of ethyl cellulose work equally well.
The first step in the operation of my invention is to prepare a base matrix mixture for the tablet. One satisfactory method of making the same is to dissolve the water-soluble and water-insoluble ingredients in a mutual volatile organic solvent, and then to evaporate the solvent so as to obtain a single homogeneous solid. In this solid the two materials, i.e., the water-soluble and the water-insoluble constituents, will be intimately, finely, extensively and thoroughly dispersed in one another. Thereafter, this homogeneous solid is milled, that is to say, reduced to fine particles, e.g., 20 mesh. At this stage, the matrix material is ready for mixing with the active ingredients and tableting. It can be stored for as long as desired and is at all times immediately available for incorporation in a tablet.
To make a tablet out of this material, the same is mixed with an active ingredient in any desired proportions, depending upon the desired rate of release and the desired amount of medication. Preferably, the amount of active ingredient does not exceed 40% by weight of the tablet and in no case should it exceed by weight. The mixing can be accomplished in conventional blenders and mixers, such as are presently employed in phar- 3 mac eutical houses. Thereafter, the mixture of the matrix material and the active ingredient are tableted in a known manner, i.e., between dies and under pressure. In the finished tablet, the active ingredient will be found to be finely, intimately, extensively and thoroughly dispersed through the matrix.
An example of the foregoing method consists in dissolving two pounds of polyethylene glycol (molecular weight of 6,000) with one pound of ethyl cellulose (2.42 to 2.53 ethyoxyl groups per anhydroglucose unit, the viscosity being 4 centipoises when determined in 5% concentration, using 80% toluene and 20% methanol as a solvent) in three gallons of methanol at room temperature. The solution then is evaporated in a vacuum drier at any suitable temperature in order to recover the methanol for reuse. If recovery is not desired, the solvent can be evaporated into the atmosphere at room temperature. The resulting homogeneous solid then is milled to a fineness of about 20 mesh.
An alternate method of making the matrix material is to heat the polyethylene glycol or the water-soluble fatty acid ester thereof so as to melt the same, and then to dissolve the ethyl cellulose in the now liquid material. The temperature employed for melting is a few degrees, a minimum of 5 C., above the melting temperature for the polyethylene glycol or its derivative, e.g., about 60 C. When the ethyl cellulose is completely dissolved and, preferably, after the mix is stirred, it is permitted to solidify by cooling, and it will be found that at such time the two materials are as finely, thoroughly, intimately and uniformly dispersed in one another as in the first method above described. Thereafter, the solid is milled and used in the manner already set forth.
-A tablet prepared in accordance with the foregoing invention Will, when ingested, be exposed to the fluids present in the alimentary canal. These are water based and, therefore, at the solid-liquid interface of the tablet and alimentary fluid a disintegrative process will be started by solution or dispersion of the water-soluble material, and also a release, therefore, of the water-insoluble material in the matrix. This will set free as much active ingredient as previously had been bound into the tablet by that amount of the water-soluble and waterinsoluble materials that have left the surface of the tablet. In other words, as the surface of the tablet gradually is disintegrated by the water present in the alimentary systern, the active ingredient content will be released into the system for assimilation thereby.
It is pointed out that the rate of disintegration of the tablet and, therefore, the rate of release of the active ingredient, can be varied by varying the composition of the matrix and, in general, the greater the percentage of water-soluble material present, the more rapid will be the rate of release and vice versa. I have found it quite simple to prepare matrices of different compositions which will give times of disintegration ranging from one hour to twenty-four hours for a single conventionally-sized tablet. As an example, a diameter tablet with oval sides containing five grains of matrix consisting of 55% ethyl cellulose and 45% polyethylene glycol, with a molecular weight of 6,000, prepared at a typical tableting compression force of 35 tons per square inch, will slowly disintegrate over a period of about four hours, it being then fully disintegrated. By varying the proportions to 50% ethyl cellulose and 50% polyethylene glycol (molecular weight 6,000), the time required for complete slow disintegration is about 2 hours. Conversely, by changing the amount of ethyl cellulose to 60% and the amount of polyethylene glycol of the same molecular weight to 40%, the time for complete slow disintegration is about 6 hours. If the amount of ethyl cellulose is 65% and that of polyethylene glycol is 35%, the time for complete slow disintegration is about 9 hours.
It also will be appreciated that the time span of dis integration may be extended or shortened bymaking the 4 weight of the tablet larger or smaller as the case may be, or by changing the shape of the tablet, the disintegration time being a function of the ratio of surface area to volume. t
It further will be appreciated that any known type of active ingredient can be utilized, examples thereof being: racemic amphetamine sulfate, dextroarn-phetamine sulfate, erythrityltetranitrate, digitoxin, acetyl salicylic acid, sodium penicillin, dihydrostreptomycin, pentobarbital, tolbutamide, aminophylline, antazoline hydrochloride, pyrilamine 'maleate, alkaloids of belladonna, bethanecholchloride, caffeine, codeine sulfate, morphine sulfate, colchicine, cortisone, meprobamate, tolazoline hydrochloride, reserpine, quinidine sulfate, quinine sulfate, pilocarpine hydrochloride progestrone, dienestrol, diethyl carbamazine citrate, ephedrine sulfate, ergonovine meleate, ethisterone, predisone, isoniazid, mercurophylline, methyltestosterone, propylthiouracil, and neostigmine bromide. The foregoing, before incorporation into the tablet, are powders. However, it even is within the scope of my invention to utilize liquid active ingredients, e.g., nitroglycerine, provided that the same are present in sufficiently small proportions to permit tableting.
As noted above, I prefer not to have the amount of active ingredient exceed by Weight of the tablet. However, this percentage can be made as small as is wanted, depending, as Will be appreciated, upon the desired rate of release of the active ingredient and the total amount present in any one tablet.
It also will be appreciated that the active ingredient may itself be carried in an inert base, particularly when very tiny amounts thereof are to be utilized, or when the active ingredient normally is supplied in such manner by chemical and pharmaceutical manufacturing concerns.
A typical example of a tablet embodying my invention is 5 mgs. of dextroamphetamine sulfate together sufficient of the matrix to make up 5 grains (325 mgs.), the matrix consisting of 65 by weight of ethyl cellulose and 35% by weight of polyethylene glycol. The tablet is compressed at 35 tons per square inch and has a diameter of A; of an inch.
Another example is a tablet of the same weight, 5 grains, the same size, and similar compression, containiug mgs. of pyrilamine maleate together with a suflicient quantity of the same matrix as used in example 1 to make up the 5 grain-s.
Still another example is a tablet of the same size, weight and compression, containing 2 mgs. of dienestrol together with enough of the same matrix to make up 5 grains.
A further example is a tablet of the same weight, size and compression, containing 0.5 mg. of reserpine together with enough of the matrix to make up to 5 grains.
Still another example is a tablet containing 200 mgs. of quinidine sulfate together with enough of the same matrix to make up an 8 grain tablet. Due to the size of the tablet, the same is /2 inch in diameter and is compressed to the same extent as aforesaid.
The matrix materials of my invention not only are non-toxic, bland, inert, palatable, and ingestible in the human system without any ill effects, but they can be stored for protracted periods of time without experiencing any chemical or physical deterioration.
Because the release of the active ingredient takes place by solution or dispersion at the surface of the tablet, and because the surface initially is largest directly following ingestion, the initial release of active ingredient is the fastest, and thereafter the rate of release gradually decreases. This is particularly desirable because it enables a rapid achievement of a therapeutic level of medication to be obtained, followed by a slowly decreasing rate of release which approximates the rate at which the body eliminates the medication.
It will be apparent that my novel matrix can be incorporated in standard tableting procedures without requiring the skilled help and special machinery that are necessary in varying the coatings on particles of active material, and that with very little additional expense, I can prepare a single tablet that, although taken only once a day, will give a steady substantially uniform release of active material for a rather long period of time. In addition to the foregoing, due to the fact that the disintegration of the tablet employing my new matrix is achieved by exposure to a water based liquid, the disintegration is substantially unaffected by the pH of such liquid. Thus, despite the fact that the tablet may be traversing almost the entire length of the alimentary canal, the rate of release of the medicament will not vary. In this respect the tablet differs from some conventional tablet-s which are specially coated to provide release only in regions of certain pHs and which, after they travel past such regions, will have no beneficial effect. However, it will be understood that, if desired, a tablet embodying my invention can be coated to prevent release of medicament initially and to permit start of release only at some certain part of the alimentary canal.
It thus will be seen that I have provided tablets and methods of making the same which achieve the various objects of my invention and are well adapted to meet the conditions of practical use.
As various possible embodiments might be made of the above invention and as various changes might be made in the embodiments above set forth, it is to be understood that all matter herein described is to be interpreted as illustrative and not in a limiting sense.
Having thus described my invention, I claim as new and desire to secure by Letters Patent:
1. A solid compressed tablet having a slow protracted medicinal effect, said tablet consisting of a matrix and an active ingredient, said matrix essentially constituting a solid solution of solid ethyl cellulose in a solid material selected from the class consisting of polyethylene glycol and water-soluble mono and di fatty acid esters thereof, said active ingredient being intimately, finely, extensively and thoroughly dispersed throughout said matrix, whereby when the tablet is ingested, the water based liquids in the alimentary canal will form a liquid-solid interface, with the surface of the tablet, whereupon the surface of the tablet will gradually be disintegrated by solution of the solid material selected from the class consisting of polyethylene glycol and water-soluble mono and di fatty acid esters thereof in the alimentary water-based liquids with the consequent release of the solid ethyl cellulose and of the active ingredient so that the tablet will slowly disintegrate at its surface to slowly and continually release the active ingredient at the said surface into the alimentary canal over a period of several hours and so that because the rate of release of the active ingredient is proportional to the surface area of the tablet and because the surface area of the tablet continually decreases in size the rate of release of the active ingredient slowly decreases.
2. A solid compressed tablet having a slow protracted medicinal effect, said tablet consisting of a matrix and an active ingredient, said matrix essentially constituting a solid mutual solution of solid polyethylene glycol having a molecular Weight of between 1,000 and 20,000 and solid ethyl cellulose having an ethyoxyl content of from 2.2 to 2.6 ethyoxyl groups per anhydroglucose unit, said active ingredient being intimately, finely, extensively and thoroughly dispersed throughout said matrix, whereby when the tablet is ingested, the water-based liquids in the alimentary canal will form a liquid-solid interface, with the surface of the tablet, whereupon the surface of the tablet will gradually be disintegrated by solution of the solid material selected from the class consisting of polyethylene glycol and water-soluble mono and di fatty acid esters thereof in the alimentary water-based liquids with the consequent release of the solid ethyl cellulose and of the active ingredient so that the tablet will' slowly disintegrate at its surface to slowly and continually release the active ingredient at the said surface into the alimentary canal over a period of several hours and so that because the rate of release of the active ingredient is proportional to the surface area of the tablet and because the surface area of the tablet continually decreases in size the rate of release of the active ingredient slowly decreases.
3. A solid compressed tablet having a slow protracted medicinal effect, said tablet consisting of a matrix and an active ingredient, said matrix essentially constituting a solid solution of a solid fatty acid ester of a polyethylene glycol having a molecular weight of between 1,000 and 20,000 and solid ethyl cellulose having an ethyoxyl content of from 2.2 to 2.6 ethyoxyl groups per anhydroglucose unit, said active ingredient being intimately, finely, extensively and thoroughly dispersed throughout said matrix, whereby when the tablet is ingested, the water-based liquids in the alimentary canal will form a liquid-solid interface, with the surface of the tablet, whereupon the surface of the tablet will gradually be disintegrated by solution of the solid material selected from the class consisting of polyethylene glycol and Water-soluble mono and di fatty acid esters thereof in the alimentary waterbased liquids with the consequent release of the solid ethyl cellulose and of the active ingredient so that the tablet will slowly disintegrate at its surface to slowly and continually release the active ingredient at the said surface into the alimentary canal over a period of several hours and so that because the rate of release of the active ingredient is proportional to the surface area of the tablet and because the surface area of the tablet continually decreases in size the rate of release of the active ingredient slowly decreases.
References Cited in the file of this patent UNITED STATES PATENTS 2,410,417 Andersen Nov. 5, 1946 2,550,622 Taub Apr. 24, 1951 2,736,682 Hermelin Feb. 28, 1956 2,791,530 Dallavis et a1. May 7, 1957 2,793,979 Svedres May 28, 1957 2,798,837 Sahyun July 9, 1957 2,805,977 Robinson Sept. 10, 1957 2,809,917 Hermelin Oct. 15, 1957 2,894,289 Harper et al. July 14, 1959 2,987,445 Levesque June 6, 1961 FOREIGN PATENTS 109,438 Australia Ian. 11, 1940 OTHER REFERENCES McClelland: Chemical and Engineering News, 23:3, February 10, 1945, page 249 relied upon.
Lesser: Drug and Cos. Ind., vol. 62, No. 6, June 1948, p. 752.
Miller: The Use of Polyethylene Glycol as a Binder in Tablet Compression, J.A.P.A Sci. Ed., vol. 43, No. 8, August 1954, pages 486-488.
Claims (1)
1. A SOLID COMPRESSED TABLET HAVING A SLOW PROTRACTED MEDICINAL EFFECT, SAID TABLET CONSISTING OF A MATRIX AND AN ACTIVE INGREDIENT, SAID MATRIX ESSENTIALLY CONSTITUTING A SOLID SOLUTION OF SOLID ETHYL CELLULOSE IN A SOLID MATERIAL SELECTED FROM THE CLASS CONSISTING OF POLYETHYLENE GLYCOL AND WATER-SOLUBLE MONO AND DI FATTY ACID ESTERS THEREOF, SAID ACTIVE INGREDIENT BEING INTIMATELY, FINELY, EXTENSIVELY AND THOROUGHLY DISPERSED THROUGHOUT SAID MATRIX, WHEREBY WHEN THE TABLET IS INGESTED, THE WATER BASED LIQUIDS IN THE ALIMENTARY CANAL WILL FORM A LIQUID-SOLID INTERFACE, WITH THE SURFACE OF THE TABLET, WHEREUPON THE SURFACE OF THE TABLET WILL GRADUALLY BE DISINTERGRATED BY SOLUTION OF THE SOLID MATERIAL SELECTED FROM THE CLASS CONSISTING OF POLYETHYLENE GLYCOL AND WATER-SOLUBLE MONO AND DI FATTY ACID ESTERS THEREOF IN THE ALIMENTARY WATER-BASED LIQUIDS WITH THE CONSEQUENT RELEASE OF THE SOLID ETHYL CELLULOSE AND OF THE ACTIVE INGREDIENT SO THANT THE TABLET WILL SLOWLY DISINTEGRATE AT ITS SURFACE TO SLOWLY AND CONTINUALLY RELEASE THE ACTIVE INGREDIENT AT THE SAID SURFACE INTO THE ALIMENTARY CANAL OVER A PERIOD OF SEVERAL HOURS AND SO THAT BECAUSE THE RATE OF RELEASE OF THE ACTIVE INGREDIENT IS PROPORTIONAL TO THE SURFACE AREA OF THE TABLET AND BECAUSE THE SURFACE AREA OF THE TABLET CONTINUALLY DECREASES IN SIZE THE RATE OF RELEASE OF THE ACTIVE INGREDIENT SLOWLY DECREASES.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US688403A US3039933A (en) | 1957-10-07 | 1957-10-07 | Ethyl cellulose-polyethylene glycol tablet matrix |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US688403A US3039933A (en) | 1957-10-07 | 1957-10-07 | Ethyl cellulose-polyethylene glycol tablet matrix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3039933A true US3039933A (en) | 1962-06-19 |
Family
ID=24764286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US688403A Expired - Lifetime US3039933A (en) | 1957-10-07 | 1957-10-07 | Ethyl cellulose-polyethylene glycol tablet matrix |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3039933A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| US3371015A (en) * | 1962-06-28 | 1968-02-27 | Haessle Ab | Pharmaceutical core compositions with thin rapidly disintegrating coatings |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| FR2035801A1 (en) * | 1968-05-21 | 1970-12-24 | American Home Prod | |
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3909444A (en) * | 1971-08-05 | 1975-09-30 | Ncr Co | Microcapsule |
| US3938515A (en) * | 1971-12-20 | 1976-02-17 | Alza Corporation | Novel drug permeable wall |
| US4308251A (en) * | 1980-01-11 | 1981-12-29 | Boots Pharmaceuticals, Inc. | Controlled release formulations of orally-active medicaments |
| GB2164556A (en) * | 1983-04-09 | 1986-03-26 | Nikken Chemicals Co Ltd | Sustained release pharmaceutical tablet of theophylline and production process therefor |
| US4673527A (en) * | 1985-05-20 | 1987-06-16 | Autotrol Corporation | Tablet granulation |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| US4960765A (en) * | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| US4980173A (en) * | 1980-03-20 | 1990-12-25 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
| US20120058965A1 (en) * | 2010-06-17 | 2012-03-08 | Goddard Iii William A | Methods and systems for modulating hormones and related methods, agents and compositions |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2410417A (en) * | 1944-03-04 | 1946-11-05 | Lever Brothers Ltd | Vitamin and mineral dietary supplement and method of making |
| US2550622A (en) * | 1947-07-11 | 1951-04-24 | Benjamin Clayton | Ointment base and iodine ointment |
| US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
| US2791530A (en) * | 1953-08-31 | 1957-05-07 | Abbott Lab | Stabilized fumagillin compositions |
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2798837A (en) * | 1952-11-20 | 1957-07-09 | Sahyun Melville | Achlorhydria composition |
| US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
| US2809917A (en) * | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical tablets |
| US2894289A (en) * | 1956-03-01 | 1959-07-14 | Dow Chemical Co | Method of making permeselective membranes |
| US2987445A (en) * | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
-
1957
- 1957-10-07 US US688403A patent/US3039933A/en not_active Expired - Lifetime
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2410417A (en) * | 1944-03-04 | 1946-11-05 | Lever Brothers Ltd | Vitamin and mineral dietary supplement and method of making |
| US2550622A (en) * | 1947-07-11 | 1951-04-24 | Benjamin Clayton | Ointment base and iodine ointment |
| US2798837A (en) * | 1952-11-20 | 1957-07-09 | Sahyun Melville | Achlorhydria composition |
| US2793979A (en) * | 1953-03-30 | 1957-05-28 | Smith Kline French Lab | Method of making a sustained release pharmaceutical tablet and product of the method |
| US2791530A (en) * | 1953-08-31 | 1957-05-07 | Abbott Lab | Stabilized fumagillin compositions |
| US2736682A (en) * | 1954-10-11 | 1956-02-28 | Victor M Hermelin | Method of making a prolonged action medicinal tablet |
| US2805977A (en) * | 1955-01-04 | 1957-09-10 | Smith Kline French Lab | Sustained release pharmaceutical preparation |
| US2809917A (en) * | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical tablets |
| US2894289A (en) * | 1956-03-01 | 1959-07-14 | Dow Chemical Co | Method of making permeselective membranes |
| US2987445A (en) * | 1958-10-10 | 1961-06-06 | Rohm & Haas | Drug composition |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| US3371015A (en) * | 1962-06-28 | 1968-02-27 | Haessle Ab | Pharmaceutical core compositions with thin rapidly disintegrating coatings |
| FR2035801A1 (en) * | 1968-05-21 | 1970-12-24 | American Home Prod | |
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US3909444A (en) * | 1971-08-05 | 1975-09-30 | Ncr Co | Microcapsule |
| US3938515A (en) * | 1971-12-20 | 1976-02-17 | Alza Corporation | Novel drug permeable wall |
| US4308251A (en) * | 1980-01-11 | 1981-12-29 | Boots Pharmaceuticals, Inc. | Controlled release formulations of orally-active medicaments |
| US4960765A (en) * | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| US4980173A (en) * | 1980-03-20 | 1990-12-25 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| US5013727A (en) * | 1980-03-20 | 1991-05-07 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| GB2164556A (en) * | 1983-04-09 | 1986-03-26 | Nikken Chemicals Co Ltd | Sustained release pharmaceutical tablet of theophylline and production process therefor |
| US5082655A (en) * | 1984-07-23 | 1992-01-21 | Zetachron, Inc. | Pharmaceutical composition for drugs subject to supercooling |
| US4673527A (en) * | 1985-05-20 | 1987-06-16 | Autotrol Corporation | Tablet granulation |
| US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| US20120058965A1 (en) * | 2010-06-17 | 2012-03-08 | Goddard Iii William A | Methods and systems for modulating hormones and related methods, agents and compositions |
| US8796233B2 (en) * | 2010-06-17 | 2014-08-05 | California Institute Of Technology | Methods and systems for modulating hormones and related methods, agents and compositions |
| US10330678B2 (en) | 2010-06-17 | 2019-06-25 | California Institute Of Technology | Methods and systems for modulating hormones and related methods, agents and compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3965256A (en) | Slow release pharmaceutical compositions | |
| US4235870A (en) | Slow release pharmaceutical compositions | |
| US8506998B2 (en) | Pharmaceutical formulation | |
| US3773920A (en) | Sustained release medicinal composition | |
| US2793979A (en) | Method of making a sustained release pharmaceutical tablet and product of the method | |
| EP0235986B1 (en) | Slow release formulation | |
| US5980942A (en) | Zero-order sustained release matrix tablet formulations of carbamazepine | |
| US3147187A (en) | Sustained release pharmaceutical | |
| EP0095123B1 (en) | Sustained release diethylpropion compositions | |
| JP3778948B2 (en) | Controlled release tablets containing water soluble drugs | |
| DE2336218C3 (en) | Oral dosage form | |
| US3632739A (en) | Solid sustained release pharmaceutical preparation | |
| US3279998A (en) | Method of preparing sustained release tablets | |
| US4254099A (en) | Pharmaceutical tablet composition | |
| RU2101009C1 (en) | Solid medicinal formula for oral use showing the delayed release of an active substance and a method of its making (variants) | |
| JPH0776171B2 (en) | Compositions for the controlled release of one or more active ingredients in a liquid and methods for their preparation | |
| JPS629A (en) | Sustained release compound unit pharmaceutical | |
| DE642785T1 (en) | Heterodisperse hydrogel systems for the delayed release of insoluble drugs. | |
| JPH0122245B2 (en) | ||
| US4150110A (en) | Coated granules of polyacrylic alkali metal salts and method of producing same | |
| US6132772A (en) | Extended-release solid oral dosage forms of drugs having low solubility in water | |
| US3328256A (en) | Spherical beads and their production | |
| JPS6248618A (en) | Slow-releasing drug preparation and production thereof | |
| JP2711528B2 (en) | Loxoprofen preparation | |
| EP0540813B1 (en) | Sustained release formulations of acetazolamide |